Project Grant R21AI182993
Award Date
4/21/25
Completion Date
3/31/27
Dollars Obligated
$188K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The primary objectives are to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in controlling TB infection and reactivation, as well as characterize the cellular mechanisms...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $727,273 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop a microfluidic multiplexed antibody profiling chip and point-of-care detection microchip for rapid and scalable diagnosis of tuberculosis (TB). The goal is to leverage machine learning to define antibody signatures that can differentiate active TB disease from latent TB infection,...
The federal Project Grant award R01AI184623, with a total funding amount of $1,091,124.00 and an award date of July 9, 2024, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand the mechanisms of efficient control of Mycobacterium tuberculosis (MTB) in the lungs prior to granuloma formation, with a goal of developing novel vaccination strategies to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,011,348 to the Texas Biomedical Research Institute over a 5-year period starting August 2024. The research project aims to investigate the early interactions between the tuberculosis bacterium (M.TB) and the human alveolar environment, particularly how exposure to the alveolar lining fluid (ALF) from people...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
This $749,414 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary awardee, The Ohio State University, is conducting research to investigate the role of the macrophage efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and its impact on tuberculosis (TB) treatment duration. The research aims to: 1) define the role of MDR1 in M.TB survival in macrophages;...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $707,176 to The University of Texas Southwestern Medical Center to study the interaction of Mycobacterium tuberculosis with upper airway mucosal cells. The key objectives of this 5-year research project are to: (1) determine the transcriptional profiles and functions of novel genes in primary human and mouse...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $838,989 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to conduct comprehensive characterization of RV0678 mutations conferring bedaquiline resistance in Mycobacterium tuberculosis. The goal is to develop an accurate molecular diagnostic test to rapidly detect bedaquiline resistance and inform treatment decisions, regardless...
This $131,474 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research focuses on studying how mutations in the glycerol kinase (glpK) gene impact MTB's lipid metabolism and drug tolerance, both in vitro under...
This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $517,185 award, with a performance period from August 1, 2024 to June 30, 2026, will fund research to characterize the immune response to tuberculosis (TB) using integrated single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will generate multi-omic data, including...